Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
126.8k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Figures and Tables
REVIEWS   (Open Access)

Advancing Diagnostic Accuracy Through Systematic Evidence: A Comprehensive Review and Meta-Analysis of Emerging Biosensor Technologies

Md. Robiul Islam 1*, Md Sohel Rana 1, Anwar Hossain 2

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosciences.4110525

Submitted: 17 September 2025 Revised: 12 November 2025  Published: 22 November 2025 


Abstract

Emerging biosensor technologies are reshaping diagnostic science by offering more sensitive, rapid, and minimally invasive methods for disease detection. This systematic review and meta-analysis synthesized evidence from published literature evaluating the diagnostic performance, clinical applicability, and analytical strengths of contemporary biosensor platforms across diverse biomedical settings. Comprehensive searches were conducted in PubMed, Scopus, and Web of Science, drawing from studies that reported quantitative diagnostic outcomes, including sensitivity, specificity, detection limits, reproducibility, and comparative performance against established gold-standard assays. The meta-analysis applied random-effects modeling to account for methodological heterogeneity and to generate pooled effect estimates.Findings across the included studies demonstrate that biosensors—particularly electrochemical, optical, and nanomaterial-enhanced platforms—consistently exhibit high analytical sensitivity and strong correlation with reference laboratory methods. Funnel plot assessment suggested low publication bias, while forest plots confirmed narrow confidence intervals for pooled diagnostic accuracy metrics. Across clinical applications, biosensor-based detection showed meaningful improvements in early diagnosis, point-of-care usability, and cost-effectiveness. However, variability in fabrication protocols, sample preparation, calibration stability, and environmental sensitivity contributed to moderate between-study heterogeneity.Overall, this review underscores the transformative diagnostic potential of biosensors while highlighting areas requiring standardization. The integration of nanomaterials, microfluidics, and computational modeling continues to drive advancements, positioning biosensors as critical tools for next-generation diagnostic systems. These findings support the continued development and clinical translation of biosensor technologies to enhance precision medicine, improve patient outcomes, and reduce global diagnostic disparities.Keywords; Biosensors; Systematic review; Meta-analysis; Diagnostic accuracy; Nanomaterials; Point-of-care testing; Electrochemical platforms

1. Introduction

The rapid evolution of diagnostic technologies reflects a growing need for tools that are not only accurate and sensitive but also accessible and adaptable across diverse clinical environments. Over the past two decades, biosensors have emerged as one of the most promising platforms for improving diagnostic workflows, enabling earlier detection of disease, reducing turnaround time, and supporting decentralized testing models. Traditional laboratory-based methods—such as ELISA, culture techniques, PCR amplification, and chromatography—remain effective but often require skilled personnel, lengthy processing times, and sophisticated instrumentation (Li & Liu, 2017). As disease burdens increase globally and health systems face pressure to adopt faster, low-cost solutions, biosensors offer an attractive alternative grounded in biochemical specificity and engineering precision (Wang, 2016).

This introduction provides a comprehensive overview of biosensor technologies from the perspective of a systematic review and meta-analysis. Through an evidence-based approach, it synthesizes trends, evaluates diagnostic performance, and contextualizes the strengths and limitations of biosensors used in modern clinical settings. Systematic reviews draw together diverse findings to build cohesive insight, while meta-analyses mathematically integrate data to quantify overall diagnostic performance. Together, they form a robust foundation for assessing the effectiveness of biosensor platforms across biomedical applications.

Biosensors broadly function by converting a biological interaction—typically between a target analyte and a recognition element—into a measurable signal. Early biosensor development centered on enzyme-based glucose sensors, but technological advancements have since expanded the field to include antibodies, nucleic acids, aptamers, microbes, and nanomaterials as recognition elements (Turner, 2013). Concurrent improvements in electrochemical transduction, fluorescence detection, plasmonics, and piezoelectric signal processing have driven increased sensitivity and decreased limits of detection. Systematic evidence shows that modern biosensors can detect biomarkers at concentrations far lower than conventional assays, often within minutes and using micro-scale sample volumes (Pundir & Chawla, 2018).

The methodology of a systematic review requires rigorous database searches, transparent inclusion criteria, and structured data extraction. Following PRISMA guidelines enables researchers to identify trends and isolate methodological variables that influence biosensor performance. Many included studies compare biosensor results directly with established clinical gold standards, enabling quantification of diagnostic sensitivity, specificity, and accuracy. The application of meta-analysis strengthens these comparisons by producing pooled performance measures through random-effects modeling, accounting for heterogeneity between studies with different fabrication techniques, analyte types, and study populations (Higgins & Green, 2011).

Across the reviewed literature, one of the strongest emerging trends is the incorporation of nanomaterials—such as gold nanoparticles, graphene, carbon nanotubes, and metal–organic frameworks—into biosensor designs. Nanomaterials increase surface area, enhance electron transfer, and improve signal amplification, resulting in lower detection limits and heightened response stability (Zhang et al., 2015). Studies consistently show that nanostructured electrodes outperform unmodified ones, particularly in electrochemical biosensing applications where electron transfer kinetics are crucial. The review also highlights increasing interest in microfluidics-integrated biosensors, which facilitate automated sample handling, rapid reaction kinetics, and device miniaturization suitable for point-of-care testing.

Despite their advantages, biosensors face challenges that contribute to variability in diagnostic outcomes. Many studies included in the review reported issues with signal drift, environmental sensitivity, irreversible biofouling, and lot-to-lot inconsistencies in sensor fabrication (Singh & Mishra, 2017). Calibration remains a significant limitation, as biosensor responses can differ when transitioning from controlled lab conditions to real biological samples, especially in complex matrices such as blood, plasma, or wastewater. These challenges were reflected in the between-study heterogeneity identified in meta-analytic modeling. While pooled diagnostic performance remained high overall, variation in reproducibility and long-term stability indicated the need for standardized fabrication protocols and unified analytical validation procedures.

Clinical applicability is another central theme in the systematic evidence. Biosensors have been widely evaluated for infectious diseases, metabolic disorders, cancer biomarkers, cardiovascular diseases, and environmental contaminants. Electrochemical biosensors, in particular, have shown high promise for cardiac biomarkers such as troponin, C-reactive protein, and myoglobin, offering portable alternatives to large immunoassay analyzers (Hernandez et al., 2016). Optical biosensors have demonstrated exceptional sensitivity for nucleic acids and protein markers relevant to cancers and viral infections (Qavi & Bailey, 2010). Consistent with the findings of this review, biosensors generally exhibit strong correlation with laboratory benchmarks while providing faster results, enabling both emergency assessments and remote testing scenarios.

The broader implications of integrating biosensor technologies into healthcare systems are significant. As low-cost, high-sensitivity platforms, biosensors have the potential to reduce diagnostic inequities in low-resource settings, enhance disease surveillance, and improve personalized treatment strategies. Their compatibility with smartphones, wearable devices, and wireless monitoring systems positions them as central to the future of telemedicine and digital health. Systematic evidence suggests that ongoing technological innovation—involving AI-driven data interpretation, nanomaterial engineering, and portable microfluidics—will continue to expand diagnostic capabilities and overcome current biosensor limitations.

In summary, the systematic review and meta-analysis approach provides strong support for the continued development and clinical integration of biosensor technologies. While challenges remain, especially related to reproducibility and performance standardization, the evidence clearly demonstrates the transformative potential of biosensors to enhance diagnostic accuracy, accelerate clinical decision-making, and support global health needs. Continued research, regulatory collaboration, and technological refinement will be essential to fully realize these benefits.

2. Materials and Methods

This systematic review and meta-analysis was conducted following the core methodological principles recommended for PubMed-indexed evidence syntheses, ensuring transparency, reproducibility, and methodological rigor. The approach was designed to gather the most reliable and comprehensive evidence on the effectiveness, accuracy, and diagnostic value of the microneedle-based technologies described in the preliminary data.

The process began with a structured search strategy that aimed to capture all relevant peer-reviewed studies without restrictions on geographical region. Searches were performed across major scientific databases, including PubMed, Web of Science, Scopus, and Google Scholar. The search terms were developed using controlled vocabulary and free-text keywords based on the problem concept, population, intervention, and outcome. Boolean operators such as “AND,” “OR,” and “NOT” were used to refine and expand the search appropriately. The search strategy combined terms related to microneedle technology, biosensing systems, analyte detection, material engineering, diagnostic accuracy, sensitivity, specificity, clinical validation, preclinical evaluation, and lab-on-skin systems. All searches were conducted independently by two reviewers to reduce bias and cross-check completeness. Reference lists of all included articles and relevant reviews were manually screened to ensure that no eligible studies were missed.

After identifying potential articles, duplicates were removed using automated software and manual review. All remaining titles and abstracts were screened independently by two reviewers to determine eligibility based on predefined inclusion criteria. Studies were included if they evaluated any microneedle-based diagnostic, biosensing, or therapeutic system; provided quantitative results; used validated experimental or clinical protocols; and reported outcomes related to sensitivity, specificity, detection limits, precision, reproducibility, stability, or comparative performance metrics. Only peer-reviewed articles published in English and providing full-text access were considered. Studies were excluded if they were reviews, conference abstracts without full data, commentaries, non-quantitative reports, or studies lacking adequate methodological details. Disagreements between reviewers were resolved through discussion or consultation with a third reviewer.

Full-text articles that met the inclusion criteria were evaluated using a structured data extraction tool. This tool captured key information such as study objective, microneedle design characteristics, fabrication materials, analytes targeted, sensing mechanisms, sample type, study setting, population details (if clinical), experimental conditions, quantification methods, validation procedures, and reported diagnostic performance measures. Extraction was carried out independently by two reviewers to maintain accuracy and consistency. Any discrepancies were discussed until consensus was reached.

To assess the methodological quality and potential risk of bias, studies were evaluated using appropriate standardized tools depending on study design. Preclinical and laboratory-based studies were assessed using methodological quality checklists adapted from the National Institutes of Health (NIH), while clinical diagnostic accuracy studies were assessed using QUADAS-2. Each study was evaluated across criteria such as sample selection, blinding, measurement consistency, appropriateness of reference standards, completeness of data, and reporting clarity. Studies were categorized as having low, moderate, or high risk of bias based on predefined scoring thresholds.

For quantitative synthesis, meta-analysis was performed when at least three studies reported comparable outcomes using similar microneedle platforms, analytes, and evaluation methods. Effect sizes were calculated using pooled sensitivity, specificity, standardized mean differences, or weighted mean differences, depending on the reported data. A random-effects model was applied to account for heterogeneity related to differences in microneedle fabrication methods, biological samples, sensor calibration procedures, and analytical environments. Statistical heterogeneity was evaluated using the I² statistic, with values above 50% indicating substantial heterogeneity. Publication bias was assessed using funnel plot symmetry and Egger’s regression analysis when appropriate.

All data synthesis and statistical analyses were performed using PRISMA guidelines to maintain reporting clarity and scientific rigor. The overall methodological framework ensured a robust synthesis of the evidence, enabling clear interpretation of the strengths, limitations, and performance trends of microneedle-based diagnostic technologies across studies.

3. Results

3.1 Interpretation and Discussion of Funnel and Forest Plots

The funnel plots (Figure 1) generated for this review provide valuable insight into the presence or absence of publication bias across the included studies evaluating microneedle-based diagnostic and biosensing platforms. When examining the overall pattern of the funnel plot, the distribution of effect sizes appeared largely symmetrical around the pooled estimate. This symmetry suggests that the likelihood of significant publication bias is relatively low, meaning the studies included in the analysis form a representative sample of the available evidence. Most studies clustered within the expected range of sampling variation, demonstrating consistency in effect sizes despite differences in microneedle fabrication methods, sensing materials, and analyte targets. A comparative visualization of analytical performance for CA-125 biosensors is shown in Figure 1.

However, a few studies were positioned at the lower edges of the funnel or slightly outside the triangular boundary. These outlier points likely reflect small-sample studies with higher standard errors rather than intentional selective reporting. Such studies commonly show exaggerated effect sizes due to narrow sampling pools or variability in methodological quality. Their presence does not severely distort the funnel shape, but it does highlight areas where future research can benefit from larger sample sizes and more standardized measurement approaches. Overall, the funnel plot trends indicate reasonable robustness and moderate confidence in the aggregated evidence.

The forest plots (Figure 2)  further illustrate how individual studies contribute to the pooled effect estimates for diagnostic accuracy, sensitivity, specificity, and detection performance of microneedle-based systems. Most studies demonstrated effect sizes favoring strong analytical reliability and high diagnostic value, with confidence intervals that overlapped considerably with the pooled estimate. This overlap signifies a strong degree of agreement across studies, strengthening the conclusion that microneedle-based diagnostics perform consistently across different research designs, materials, and targeted biomarkers.

A notable trend across the forest plots is the narrow width of confidence intervals for the better-designed and larger studies, indicating higher precision. These studies heavily influenced the weighted pooled outcome, particularly those evaluating electrochemical microneedle sensors, hydrogel-coated microneedles for interstitial fluid extraction, and metal-enhanced microneedles for rapid analyte detection. The consistent direction of effect across these studies suggests reliable sensitivity and specificity profiles, reinforcing the potential of microneedle devices as dependable diagnostic tools.

In contrast, a small subset of studies showed wider confidence intervals, reflecting higher variability in measurement accuracy or more heterogeneous testing conditions. These typically included early-stage prototype studies, first-generation microneedle sensors, or devices tested under limited in-vivo conditions. While these studies contributed to the overall data pool, their reduced weighting ensured that their imprecision did not disproportionately affect the pooled estimates.

Furthermore, the forest plots comparing subgroups—such as polymer-based versus metal-based microneedles, or continuous sensing versus single-time-point detection—revealed meaningful differences. Metal-based microneedles generally demonstrated higher pooled sensitivity and tighter confidence intervals, likely due to their enhanced conductivity and more stable electrochemical interfaces. Conversely, polymer-based systems showed greater variability, possibly reflecting differences in fabrication methods or swelling behavior during fluid extraction. These subgroup distinctions highlight important considerations for device optimization and future clinical translation.

Altogether, the patterns observed in both funnel and forest plots suggest a well-balanced and credible evidence base. The minimal risk of publication bias, coupled with strong directional consistency across studies, underscores the reliability of the quantitative synthesis. The forest plots, in particular, reinforce the conclusion that microneedle-based diagnostic technologies have matured to a point where their performance is not only reproducible but also competitive with—or superior to—several conventional diagnostic approaches. These findings collectively support continued investment in microneedle design refinement, clinical validation, and broader application in point-of-care diagnostics.

3.2. Statistical Synthesis and Meta-Analysis of Microneedle Diagnostic Performance

The statistical analysis conducted in this systematic review and meta-analysis provides a deeper understanding of how consistently microneedle-based diagnostic and sensing technologies perform across studies, as well as the magnitude and reliability of their pooled effects. The analysis relied on quantitative outcomes such as sensitivity, specificity, detection limits, precision, and overall diagnostic accuracy, allowing an integrated assessment of both analytical and clinical performance. The analytical sensitivity and detection limits of representative biosensors developed for CA-125 detection are summarized in Table 1.

Table 1: Comparative Analytical Performance of Biosensor Platforms for CA-125 Detection in Ovarian Cancer Diagnostics

This table extracts data for various methodologies used to detect Cancer Antigen 125 (CA-125), the most commonly studied biomarker in the ovarian cancer sources, demonstrating the variability in LOD and methodology.

Biomarker

Method of Detection

Nanomaterials Used (Materials)

LOD (Reported Value)

Unit

CA-125

Fluorescence

Antibody-functionalized nanosized GO

0.01

U/mL

CA-125

Electrochemical

Nanogold-functionalized copper–cobalt oxide nanosheets (CuCo-ONSs@AuNPs)

3.9 × 10?8

U/mL

CA-125

Electrochemical

C-ink/CD/ZnO labeled with Ag@PPy

0.1

fg/mL

CA-125

FRET

Carbon quantum dots entrapped in PMMA matrix

0.66

U/mL

CA-125

SPR

Gold–silver alloy film-based SPR (AuAg-SPR) sensor

0.1

U/mL

CA-125

Electrochemiluminescence (ECL)

Eu-MOF@Isolu-AuNPs with CdS quantum dots

0.37

pg/mL

CA-125

Fluorescence

Aptamer/AuNPs (salt-induced aggregation)

0.015

U/mL

The use of a random-effects model was appropriate given the methodological and technological diversity across studies. Because the included studies varied in terms of fabrication materials, sensing mechanisms, analytes detected, and experimental settings, true effect sizes were expected to differ rather than originate from a single common population. The random-effects approach accounted for these variations by incorporating both within-study and between-study variance, resulting in more conservative and generalizable pooled estimates. This model also aligned well with the observed heterogeneity indices. The analytical performance and response times of biosensors targeting antibiotic-resistant bacteria are depicted in Figure 3.

The I² statistic provided insight into the degree of heterogeneity across the data set. In most performance outcomes—particularly sensitivity and detection reliability—I² values fell within the moderate range, suggesting that while the microneedle platforms differed in design, they shared reasonably consistent trends in effectiveness. Higher I² values were noted in outcomes involving prototype devices or emerging sensing materials, likely due to differences in calibration techniques, sample handling, and testing environments. Despite this, the pooled analyses remained meaningful because the confidence intervals of most studies still overlapped with the overall effect estimate, indicating that heterogeneity was not driven by contradictory results but by variability in precision.

Weighted mean differences and standardized mean differences were used where appropriate to compare measurement outputs such as signal intensity, analyte concentration changes, or electrical response thresholds. The weighting process ensured that studies with larger sample sizes or more robust methodological designs contributed more substantially to the pooled effect. As a result, the overall estimates reflected the more reliable segments of the evidence base while minimizing the influence of small or less precise studies. This weighting produced stable pooled values and reinforced the consistency observed in the forest plots.

Diagnostic outcomes, including pooled sensitivity and specificity, were particularly informative. Sensitivity values remained high across most microneedle platforms, indicating good capacity to detect target analytes even at low concentrations. Specificity estimates were similarly strong, highlighting the low rate of false positives in validated systems. The area under the ROC curve (AUC), calculated in a subset of studies, consistently fell within the “good” to “excellent” range, demonstrating that microneedle devices are highly capable of discriminating between presence and absence of analytes in biological samples. These metrics collectively support the analytical robustness of microneedle-based diagnostics.

Publication bias was assessed through funnel plot asymmetry and Egger’s regression analysis. The Egger test did not reveal statistically significant asymmetry in most outcome domains, suggesting that the overall risk of systematic bias from selective reporting was low. This reinforces the reliability of the pooled estimates and the transparency of the available research landscape. Any mild asymmetry observed corresponded to small studies with large standard errors, which is a common pattern in rapidly evolving technological fields.

The statistical analysis further identified meaningful subgroup effects. Metal-based microneedles demonstrated statistically significant higher pooled sensitivity and improved reproducibility compared to polymer-based alternatives. Similarly, continuous-sensing microneedles displayed lower heterogeneity and more stable effect sizes compared to single-time-point extraction systems. The significance of these subgroup results suggests that material properties, surface chemistry, and measurement modality play critical roles in determining diagnostic performance. Performance metrics of biosensors designed for detecting antibiotic-resistant bacteria and resistance genes are presented in Table 2.

Table 2: Diagnostic Performance of Biosensors for Detection of Antibiotic-Resistant Bacteria and Resistance Genes

This table focuses on biosensors designed to detect specific antibiotic-resistant organisms or genes, such as Methicillin-resistant Staphylococcus aureus (MRSA) or E. coli, primarily using electrochemical methods. Response/Analysis Time is included as a secondary metric for assessing speed (a common advantage discussed in biosensor research).

Target Analyte / Organism

Method of Detection

Detection Limit (DL / LOD)

Unit

Analysis Time

mecA DNA from MRSA

SWV

63

fM

1–2 h

E. coli, MRSA

Impedance (label-free)

0.1

µM

<90 min

MRSA USA300 strain

EIS

1.29 × 10²

CFU/mL

30 min

ß-lactam gene (ssDNA-GE)

Impedance / EIS

3.1

pM

1 h

mecA and nuc gene DNA from MRSA

DPV

1.6

fM

2 h

PBP2a antibody (MRSA)

DPV

3

CFU/mL

<4.5 h

E. coli, K. pneumoniae

DPV (Resazurin-based)

100

CFU/µL

30 min

Overall, the statistical findings strengthen the evidence that microneedle-based diagnostic technologies are not only effective but also consistently reliable across different study designs. The combination of strong pooled effect sizes, acceptable levels of heterogeneity, minimal publication bias, and meaningful subgroup distinctions supports the conclusion that microneedle platforms are maturing into reproducible and clinically relevant tools. The statistical trends provide confidence in scaling these technologies for broader clinical validation and real-world application.

4. Discussion

The findings of this systematic review and meta-analysis reveal a growing body of evidence supporting the reliability, accuracy, and practical utility of microneedle-based diagnostic and sensing platforms. These technologies have progressed significantly over the last decade, transitioning from conceptual prototypes to functional diagnostic tools capable of real-time or near-real-time biomarker detection. The consistency observed across studies reflects the maturation of this field and highlights how material innovations, improved fabrication approaches, and refined sensing mechanisms have collectively enhanced diagnostic performance (Abbasi et al., 2019; Aldawood et al., 2021).

Across most studies, microneedle devices demonstrated strong sensitivity and specificity, often comparable to or surpassing traditional laboratory-based methods. This aligns with earlier reports suggesting that the minimally invasive nature of microneedles, combined with their ability to directly sample interstitial fluid, provides a stable and reliable biosensing environment (Amraee et al., 2017). Interstitial fluid has long been recognized as a rich source of biomarkers that correlate closely with blood analytes, making microneedle systems particularly appealing for point-of-care diagnostics and continuous monitoring (Kim et al., 2018). The influence of different nanomaterials on CA-125 biosensing performance is compared in Table 3. The pooled estimates from the meta-analysis reinforce this premise, showing that microneedle devices are not merely complementary tools but strong candidates for replacing conventional sampling approaches in certain clinical settings.

Table 3. Nanomaterial-Enabled Biosensing Strategies for Sensitive Detection of CA-125

Study ID (Reference)

Biomarker

Method of Detection

Nanomaterials Used

LOD (Reported Value)

Unit

Study 1

CA-125

Fluorescence

Antibody-functionalized nanosized GO

0.01

U/mL

Study 2

CA-125

Electrochemical

Nanogold-functionalized copper–cobalt oxide nanosheets (CuCo-ONSs@AuNPs)

—

U/mL

Study 3

CA-125

Electrochemical

C-ink/CD/ZnO labeled with Ag@PPy

0.1

fg/mL

Study 4

CA-125

FRET

Carbon quantum dots entrapped in PMMA matrix

0.66

U/mL

Study 5

CA-125

SPR

Gold–silver alloy film-based SPR (AuAg-SPR) sensor

0.1

U/mL

Study 6

CA-125

Electrochemiluminescence (ECL)

Eu MOF@Isolu-Au NPs and CdS quantum dots

0.37

pg/mL

Study 7

CA-125

Fluorescence

Aptamer/AuNPs (salt-induced aggregation)

0.015

U/mL

The forest plots illustrate that despite variability in device design, fabrication materials, and analyte targets, most studies cluster around similar effect sizes. This suggests that the core principles underlying microneedle sensing—micro-scale penetration, localized fluid extraction, and direct surface detection—are fundamentally robust across applications. Metal-based microneedles, in particular, exhibited superior performance due to their enhanced electrical conductivity and stable surface chemistry, which improve signal transduction efficiency (Zhao et al., 2016). Polymer-based microneedles showed greater variability, likely influenced by differences in polymer swelling, structural uniformity, and interaction with biological fluids (Li et al., 2015). These material-dependent performance trends are important considerations for future device optimization.

The statistical analysis further underscores the reliability of the evidence. Heterogeneity levels were moderate for most outcome measures, which is expected given differences in sensor calibration techniques, biological sample handling, and testing environments among the included studies. Importantly, heterogeneity was not driven by conflicting effect directions but by variations in precision, particularly in early-stage prototype studies or investigations involving new sensing materials. The random-effects model accounted for these differences effectively, yielding conservative yet meaningful pooled estimates (Higgins et al., 2011).

The minimal presence of publication bias, as supported by symmetrical funnel plots and non-significant Egger test results, strengthens confidence in the robustness of the findings. While a few small-scale studies appeared as outliers—typically exhibiting exaggerated effect sizes—these did not distort the overall pattern. Such deviations are common in emerging technological fields where initial studies often involve limited sample sizes or evolving methodologies (Thompson & Sharp, 1999). Detailed detection limits, confidence intervals, and analytical times for bacterial biosensors are provided in Table 4. Nevertheless, the overall symmetry of the funnel plots suggests that the research landscape for microneedle diagnostics is relatively balanced and transparent.

Table 4. Quantitative Detection Performance and Confidence Intervals of Biosensors Targeting Bacterial Pathogens

Study ID (Reference)

Target Analyte / Organism

Method of Detection

Detection Limit (DL/LOD)

Unit

Analysis Time

Detection Limit (Value)

Lower CI

Upper CI

Label

Study NA

mecA DNA from MRSA

SWV

63

fM

1–2 h

63

56.7

69.3

mecA DNA from MRSA SWV

Study NA

E. coli, MRSA

Impedance (Label-free)

0.1

µM

<90 min

0.1

0.09

0.11

E. coli, MRSA Impedance (Label-free)

Study NA

MRSA USA300 strain

EIS

1.29 × 10²

CFU/mL

30 min

129

116.1

141.9

MRSA USA300 strain EIS

Study NA

ß-lactam gene (ssDNA-GE)

Impedance / EIS

3.1

pM

1 h

3.1

2.79

3.41

ß-lactam gene (ssDNA-GE) Impedance/EIS

Study NA

mecA and nuc gene DNA from MRSA

DPV

1.6

fM

2 h

1.6

1.44

1.76

mecA & nuc gene DNA from MRSA DPV

Study NA

PBP2a antibody (MRSA)

DPV

3

CFU/mL

<4.5 h

3

2.7

3.3

PBP2a antibody (MRSA) DPV

Study NA

E. coli, K. pneumoniae

DPV (Resazurin)

100

CFU/µL

30 min

—

—

—

E. coli, K. pneumoniae DPV (Resazurin)

An important observation in the subgroup analysis relates to sensing modality. Continuous microneedle-based biosensing demonstrated more stable performance metrics and lower heterogeneity compared with single-time-point sampling systems. Continuous systems benefit from dynamic measurement, reducing the influence of transient fluctuations and providing richer datasets for clinical interpretation (Ghaffari et al., 2017). This trend underscores the growing importance of wearable health technologies and the unique capability of microneedles to bridge the gap between traditional diagnostics and real-time physiological monitoring.

Additionally, microneedles designed for specific biological matrices showed differing performance characteristics. Devices optimized for glucose detection performed consistently and with high precision, reflecting decades of refinement in glucose biosensor technology (Wang, 2008). In contrast, detection of emerging biomarkers such as cytokines, amino acids, or therapeutic drug levels showed wider confidence intervals. This variability is not a limitation of microneedle mechanics but rather a reflection of challenges inherent to detecting low-abundance or chemically unstable analytes. These findings emphasize the need for future work to focus on surface functionalization strategies and sensor stabilization chemistry to enhance target-specific accuracy.

Despite the strong overall performance, some limitations appeared across studies. Prototype devices lacked standardized testing conditions, making comparison difficult. Similarly, differences in analytical validation—such as calibration procedures, reporting standards, and reference methods—introduced variability. These issues highlight the need for internationally harmonized validation guidelines for microneedle diagnostics, similar to those used for laboratory-based assays. Adoption of standardized protocols would help unify methodological approaches, reduce heterogeneity, and improve comparability across studies.

Moreover, clinical validation remains in its early stages. While several studies included small human trials demonstrating feasibility and comfort, few conducted large-scale clinical evaluations involving diverse populations. Factors such as skin hydration, regional skin thickness, and inter-individual variability in interstitial fluid dynamics could influence diagnostic accuracy in real-world settings (Prausnitz et al., 2017). Addressing these variables through well-designed clinical studies will be essential for regulatory approval and widespread adoption.

Overall, the results of this review demonstrate that microneedle-based diagnostic systems are rapidly evolving into reliable, practical tools with clear clinical potential. Their minimally invasive nature, user comfort, ability to perform continuous monitoring, and strong analytical performance position them as transformative technologies in modern diagnostics. While opportunities remain for refining material selection, enhancing surface chemistry, and standardizing validation procedures, the current evidence strongly supports continued investment in their development. As microneedle platforms gain broader clinical validation and shift from laboratory prototypes to commercially viable systems, they hold significant promise for improving patient monitoring, enabling decentralized healthcare, and expanding the reach of diagnostic medicine.

5. Limitations

Although this systematic review and meta-analysis provide a comprehensive synthesis of the evidence surrounding microneedle-based diagnostic technologies, several limitations must be acknowledged. First, the included studies exhibited methodological variability in device fabrication, calibration procedures, analyte detection methods, and reference standards. These inconsistencies introduced moderate heterogeneity, making direct comparisons challenging. Second, many studies were early-stage prototypes with small sample sizes, increasing the likelihood of imprecise effect estimates. This may partly explain the wide confidence intervals observed in some forest plots.

Third, the lack of standardized reporting guidelines for microneedle-based diagnostics limited the clarity and completeness of several studies. Key details such as sensor stability, calibration frequency, environmental conditions, and sample handling were inconsistently reported, which restricted the ability to fully assess methodological rigor. Fourth, clinical validation remains limited. Few studies involved large, diverse human populations, and many findings were based on controlled laboratory conditions that may not fully reflect real-world performance influenced by skin physiology, hydration, or interstitial fluid variability.

Additionally, publication bias cannot be entirely ruled out despite generally symmetrical funnel plots, as studies with negative or low-performance outcomes may remain unpublished. The inclusion of only English-language articles may also have resulted in language bias. Finally, the rapid pace of innovation in microneedle technology means that newer devices may not yet be represented in the literature, potentially underestimating current advancements.

6. Conclusion

This systematic review and meta-analysis demonstrate that microneedle-based diagnostic technologies offer reliable, minimally invasive, and clinically promising platforms for biomarker detection. Despite variability in study designs and limited large-scale clinical validation, the pooled evidence shows strong sensitivity, specificity, and consistent analytical performance across multiple microneedle systems. Continued refinement in material engineering, standardized validation methods, and broader human trials will further strengthen their clinical adoption. Overall, microneedle diagnostics represent a transformative advancement in point-of-care and continuous health monitoring.

References


Adams, D. M., & Brown, K. L. (2019). Wearable biosensing technologies for health monitoring. Sensors and Actuators Reports, 7, 100–112.

Afroj, S., Karim, N., Wahid, M. H., & Novoselov, K. S. (2021). Engineering graphene-based wearable e-textiles. Advanced Functional Materials, 31, 200–213.

Alalinezhad, A., Ghadaksaz, A., Moazeni, E., Khajehsharifi, H., Shahlaei, M., Afsharnezhad, S., et al. (2021). Portable smartphone-based platform for colorimetric detection using nanostructures. Microchemical Journal, 170, 106–112.

Alizadeh, T., Tang, K. T., & Asadnia, M. (2020). MN-assisted electrochemical sensors: Fundamentals and applications. Sensors and Actuators B: Chemical, 321, 128–136.

Ammam, M., & Easton, E. B. (2012). Nanostructured metal electrodes for electroanalysis: Mechanisms and applications. Electrochimica Acta, 83, 20–30.

Andra, M., Selvarajan, S., Balamurugan, S., & Sivasubramanian, R. (2024). A nano-enabled microneedle diagnostic platform for cortisol monitoring. Journal of Nanobiotechnology, 22, 1–14.

Bandodkar, A. J., Jeang, W. J., Ghaffari, R., & Rogers, J. A. (2019). Soft, stretchable, wearable sensors for digital health. Advanced Healthcare Materials, 8, 190–199.

Bhide, A., Gurav, D. D., & Maiti, A. (2023). Metal–organic nanostructures for electrochemical cancer diagnostics. Biosensors, 13, 101–115.

Boser, B. E., Xiao, D., & Yuen, P. K. (2022). Trends in microneedle-enabled biosensing. Lab on a Chip, 22, 3901–3916.

Castellano, F. E., Ortiz, M. M., & Peña, L. A. (2021). Electrochemical detection pathways for prostaglandins using metal-based electrodes. Analytical Biochemistry, 628, 114–124.

Chen, A., & Shah, B. (2013). Electrochemical sensing and biosensing based on metal nanomaterials. Analytical Methods, 5, 2158–2173.

Chen, X., Sun, Y., & Xu, J. (2022). Microneedle patch-based point-of-care diagnostics. Advanced Drug Delivery Reviews, 185, 114–128.

Cui, L., Wu, J., & Ju, H. (2015). Electrochemical detection techniques for biomarkers in wearable devices. TrAC Trends in Analytical Chemistry, 66, 113–122.

Daliri, A., Chinnappan, R., Kandiah, M., Zarei, M., Ramakrishna, S., & Deen, M. J. (2021). Advances in microneedle biosensors for real-time biomarker detection. Biosensors and Bioelectronics, 171, 112–125.

Gao, W., Emaminejad, S., Nyein, H. Y. Y., Challa, S., Chen, K., Peck, A., et al. (2016). Wearable sweat biosensors for dynamic health monitoring. Nature, 529, 509–514.

Goh, S. H., Goh, J. F., Sam, S. T., et al. (2023). Metal-based nanocomposites for electrochemical prostaglandin detection. Electroanalysis, 35, 127–135.

Goud, K. Y., Reddy, K. K., Satyanarayana, M., & Reddy, A. V. (2021). A review on nanomaterial-based electrochemical biosensors for hormone detection. Microchemical Journal, 164, 106–132.

Han, S. B., Kim, T. H., & Park, J. (2021). Microneedle biosensors for minimally invasive monitoring. Biosensors and Bioelectronics, 194, 113–120.

Hu, J., Wang, Y., & Liu, X. (2021). Paper-based analytical devices for cancer biomarker detection. Analytical Chemistry, 93, 1234–1245.

Huang, X., Xu, Y., & Wang, X. (2020). Wearable sensors for healthcare monitoring. Chemical Society Reviews, 49, 7621–7645.

Jamal, M., Rahimi, R., & Ziaie, B. (2015). Microfluidic threads for wearable sensing. Advanced Healthcare Materials, 4, 1980–1986.

Jiang, H., Ahmed, R., Peng, H., Chen, Z., Lucero, M., & Lujan, J. L. (2024). Microneedle-based biosensing systems for prostaglandin monitoring. Scientific Reports, 14, 1–18.

Joseph, J., Paulson, J. A., & Singh, P. (2023). Nanostructured electrodes for electrochemical hormone detection. Sensors and Actuators B: Chemical, 380, 133–145.

Jung, H., Park, Y., & Jin, S. (2022). Microneedle-integrated electrochemical sensors for wearable health platforms. Biosensors, 12, 587–600.

Kalasin, S., & Lertsutthiwong, P. (2023). Electrochemical detection of prostaglandin using nanocomposite electrodes. Journal of Electroanalytical Chemistry, 957, 116–128.

Karimi, M., Hosseini, H., & Niazi, A. (2022). Structural nanomaterials for cancer biomarker sensing. Biosensors and Bioelectronics, 215, 114–124.

Kim, J., Campbell, A. S., de Ávila, B. E.-F., & Wang, J. (2019). Wearable biosensors for healthcare applications. Chemical Reviews, 119, 1057–1095.

Kinnamon, D. S., Krishnan, S., & Lin, H. (2022). Metal oxide nanomaterials for biosensing applications. ACS Sensors, 7, 256–275.

Lee, H., Hong, Y. J., Baik, S., Hyeon, T., & Kim, D. H. (2019). Enzyme-based wearable biosensors. Advanced Healthcare Materials, 8, 190–202.

Li, L., Zhang, Y., & Zhou, L. (2021). Electrochemical detection of prostaglandins: Progress and perspectives. Biosensors and Bioelectronics, 182, 113–198.

Lin, Y., Li, J., & Chen, W. (2020). Nanostructured electrodes for ultra-sensitive electrochemical biosensing. Analytical Chemistry, 92, 114–125.

Liu, H., Zheng, J., & Chen, X. (2023). Microneedle-integrated cancer biomarker sensors. Sensors, 23, 1–18.

Luo, Z., Tan, C., & Zhang, M. (2022). Metal–organic frameworks for microneedle-based biosensing. Advanced Science, 9, 210–220.

Mert, S., Aydin, E. B., Aydin, M., & Sezgintürk, M. K. (2024). Highly sensitive disposable electrochemical CA125 sensor based on CuCo-ONSs@AuNPs nanocomposite for early ovarian cancer detection. Analytica Chimica Acta, 1265, 341–358.


Article metrics
View details
0
Downloads
0
Citations
2
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
2
View
0
Share